EGFR exon 19 deletion + EGFR G724S
|
Lung Cancer
|
EGFR exon 19 deletion + EGFR G724S
|
Lung Cancer
|
dacomitinib Sensitive: C4 – Case Studies
Invest New Drugs - 4 weeks (New C4)
|
dacomitinib Sensitive: C4 – Case Studies
Invest New Drugs - 4 weeks - (New C4)
|
EGFR exon 19 deletion + EGFR G724S
|
NSCLC
|
EGFR exon 19 deletion + EGFR G724S
|
NSCLC
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion + EGFR G724S
|
NSCLC
|
EGFR exon 19 deletion + EGFR G724S
|
NSCLC
|
dacomitinib Resistant: C3 – Early Trials
|
dacomitinib Resistant: C3 – Early Trials
|